Swipe Left For English News
1
标普全球企业可持续发展评估（CSA）得分位居前1%
2
连续三年同时入选全球及中国版《可持续发展年鉴》
3
引领绿色生物药发展，赋能全球客户迈向ESG发展新高度
上海,
2025年5月19日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司入选2025年标普全球《可持续发展年鉴（中国版）》。该年鉴于2025年5月13日在深圳举办的标普全球Sustainable1论坛正式发布。
标普全球《可持续发展年鉴》以标普全球企业可持续发展评估（CSA）评分结果为基础，衡量企业可持续发展绩效，识别各行业可持续发展表现优异的企业。
药明生物连续三年凭借位居前1%的CSA得分，同时入选《全球可持续发展年鉴》及《可持续发展年鉴（中国版）》，彰显了公司在推动可持续发展进程中的坚定承诺与显著成就。
Dave Erbsberger
Mark Eramo
大宗商品联席总裁
标普全球
我们向参与2024年CSA评估的所有企业表示衷心感谢，并为这些企业将可持续发展作为当前运营和未来战略核心原则的决心和韧劲所鼓舞。感谢所有企业不断致力于在透明度、责任担当与创新实践方面的可持续发展承诺，这些努力对推动变革与成功至关重要。
陈智胜博士
首席执行官
ESG委员会主席
药明生物
我们非常荣幸再次入选《可持续发展年鉴》，这彰显了公司持续深化可持续发展绩效的不懈努力。作为绿色生物药解决方案领域的全球领导者，我们始终秉持卓越的ESG理念，并赋能全球合作伙伴，助力其迈向ESG发展新高度，共同推动整个价值链的可持续发展。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物凭借出色的表现获得了权威评级机构的广泛认可。公司连续两年获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）、CDP水安全管理A级榜单、CDP气候变化A-领导力评分；连续五年获评晨星Sustainalytics ESG“行业最高评级”及“区域最高评级”；入选富时社会责任指数系列及恒生ESG 50指数，获得ISS ESG评级“最佳”奖章认可等，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Included in S&P Global Sustainability Yearbook (China Edition) for Third Consecutive Year
1
S&P Global CSA score ranking in Top 1%
2
Inclusion in both Global Yearbook and China Yearbook for third consecutive year
3
Green CRDMO solutions to empower global clients on their sustainability journeys
Shanghai,
May 19, 2025
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the 2025 S&P Global Sustainability Yearbook (China Edition), which was launched at the S&P Global Sustainable1 forum in Shenzhen on May 13, 2025.
The Sustainability Yearbook recognizes companies within their industries that have demonstrated strengths in corporate sustainability. Yearbook members are selected and their distinction levels determined based on their score in the annual S&P Global Corporate Sustainability Assessment (CSA).
For the third consecutive year, WuXi Biologics achieved a CSA score placing it in the Top 1% ranking, and was selected for inclusion in both the Global Sustainability Yearbook and the Sustainability Yearbook (China Edition), demonstrating its steadfast commitment to and significant advancements in driving sustainable development.
Dave Erbsberger
Mark Eramo
Commodity Insights Co-President
S&P Global
We extend our gratitude to all the companies that participated in CSA, and are inspired by their dedication and resilience that have embraced sustainability as a core principle of current operations and forward-looking strategies. Your commitment to transparency, accountability, and innovation is vital in driving change and success.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to be once again selected for the Yearbook, a reflection of our continued dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable clients worldwide to fulfill ESG commitments, and work with all stakeholders to promote responsible practices throughout the entire value chain.
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A list" and awarded an A- CDP Climate Change leadership-level score for two consecutive years; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
